Healthcare / Medical DevicesUpdated 2026-05-10 22:07 UTC

CPH/VIRO stock hub

CPH/VIRO has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CPH/VIROis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

94.7M

Copenhagen Stock Exchange

Market data

Price

Recent price action with selectable time range.

CPH/VIROCPH/VIRO

—

Loading chart…

In the news

Latest news · CPH/VIRO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-82.4

P25 n/aP50 n/aP75 n/a

ROIC-38.6

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CPH/VIRO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

160

Groups with data

Currency

DKK

Showing 160 of 160 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Denmark
Country code	DK
Employees	7
Employees Change	-3%
Employees Change Percent	-30
Enterprise value	DKK 76.6M
Exchange	Copenhagen Stock Exchange
Financial currency	DKK
First seen	2026-05-10
Industry	Medical Devices
Isin	DK0061030574
Last refreshed	2026-05-10
Market cap	DKK 94.7M
Price	DKK 10.2
Price currency	DKK
Rev Per Employee	1,286,428.57x
Sector	Healthcare
Sic	3845
Symbol	cph/VIRO
Website	https://www.virogates.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-10.8%
EV Earnings	-7.49x
EV/Sales	8.51x
P/B ratio	5.64x
P/S ratio	10.51x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-117.58%
Gross margin	78.46%
Gross Profit	DKK 7.1M
Gross Profit Growth	70.86%
Gross Profit Growth Q	83.46%
Gross Profit Growth3 Y	-14.13%
Gross Profit Growth5 Y	5.08%
Net Income	DKK -10.2M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Pretax Margin	-124.35%
Profit Margin	-113.54%
Profit Per Employee	DKK -1.5M
ROA	-30.93
Roa5y	-36.72
ROCE	-53.45
ROE	-82.44
Roe5y	-75.7
ROIC	-38.56

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	56.97%
Cagr3y	-16.71%
Cagr5y	-42.91%
EPS Growth Quarters	4
EPS Growth Years	2
Revenue Growth	32.27x
Revenue Growth Q	8.4x
Revenue Growth Quarters	1x
Revenue Growth Years	1x
Revenue Growth3 Y	-11.73x
Revenue Growth5 Y	5.21x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	DKK 0.42
Assets	DKK 26.8M
Cash	DKK 22.3M
Current Assets	DKK 26.6M
Current Liabilities	DKK 7M
Debt	DKK 4.2M
Debt Equity	DKK 0.25
Equity	DKK 16.8M
Interest Coverage	-16.19
Liabilities	DKK 10M
Long Term Assets	DKK 186,000
Long Term Liabilities	DKK 3M
Net Cash	DKK 18.1M
Net Cash By Market Cap	DKK 19.07
Net Cash Growth	204.71%
Net Debt Equity	DKK -1.08
Tangible Book Value	DKK 16.8M
WACC	8.03

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.82
Inventory Turnover	1.03
Net Working Capital	DKK -1.5M
Quick ratio	3.5
Working Capital	DKK 19.6M
Working Capital Turnover	DKK 0.57

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	56.92%
200-day SMA	11.81
3Y total return	-42.23%
50-day SMA	11.33
50-day SMA vs 200-day SMA	50under200
5Y total return	-93.93%
All Time High	252
All Time High Change	-95.95%
All Time High Date	2021-05-05
All Time Low	4.98
All Time Low Change	104.82%
All Time Low Date	2023-12-21
ATR	0.84
Beta	0.65
Beta1y	-1.02
Beta2y	-0.26
Ch YTD	-24.16
High	10.2
High52	17.4
High52 Date	2025-11-26
High52ch	-41.38%
Low	10.1
Low52	6.5
Low52 Date	2025-05-14
Low52ch	56.92%
Ma50ch	-9.97%
Price vs 200-day SMA	-13.65%
RSI	45.57
RSI Monthly	42.88
RSI Weekly	42.34
Sharpe ratio	0.82x
Sortino ratio	1.56
Tr YTD	-24.16
Tr1m	-3.77%
Tr1w	-9.73%
Tr3m	-16.39%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	DKK -10.6M
Operating margin	-117.6

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,365,354%
Net Borrowing	-1,077,000
Shares Insiders	45.74%
Shares Out	9,281,891

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	946.05x
Ch1m	-3.77
Ch1w	-9.73
Ch1y	56.92
Ch3m	-16.39
Ch3y	-55.46
Ch5y	-95.32
Ch6m	-15.7
Change	-6.42%
Change From Open	0.99
Close	10.9
Days Gap	-7.34
Dollar Volume	877.2
Earnings Date	2026-05-07
EBIT	DKK -10.6M
F Score	4
Financing CF	17,927,000
Fiscal Year End	December
Founded	2,000
Income Tax	DKK -974,000
Investing CF	5,000
Is Primary Listing	1
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Ma150	12.24
Ma150ch	-16.63%
Ma20	10.72
Ma20ch	-4.81%
Net CF	11,054,000
Next Earnings Date	2026-08-20
Open	10.1
Position In Range	100
Price Date	2026-05-08
Ptbv Ratio	5.64
Relative Volume	0.09x
Revenue	9,005,000x
Tax By Revenue	-10.82x
Tr6m	-15.7%
Volume	86

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CPH/VIRO pay a dividend?

Capital-return profile for this ticker.

Performance

CPH/VIRO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CPH/VIRO?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

+45.7%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

n/a

Negative means the company is buying back shares.

Technical

CPH/VIRO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.6

Neutral momentum band

Price vs 200-day MA

-13.7%

50/200-day relationship not available

Beta (5Y)

0.65

Less volatile than the market

Sharpe ratio

0.82

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CPH/VIRO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current cph/VIRO stock rating?

cph/VIRO is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full cph/VIRO analysis?

The full report lives at /stocks/cph/VIRO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for cph/VIRO?

The latest report frames cph/VIRO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the cph/VIRO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.